Matasar Highlights Good News in Follicular Lymphoma


Matthew Matasar, MD, discusses the development of mosunetuzumab and how it is a positive step forward in the field of follicular lymphoma treatment.

Matthew Matasar, MD, chief of the Division of Blood Disorders at the Rutgers Cancer Institute and professor at the Rutgers Robert Wood Johnson Medical School, discusses the development of mosunetuzumab (Lunsumio) and how it is serving as good news in the follicular lymphoma treatment field.

One of the biggest, most recent updates in the follicular lymphoma space has been with the development of mosunetuzumab. In December 2022, the FDA granted approval to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy. This approval was based on data from the phase 2 GO29781 study (NCT02500407) which enrolled 90 patients with follicular lymphoma that was grade I to IIIA. Patients must have had an ECOG performance status of 0 to 1 and received of at least 2 prior lines of therapy, including an anti-CD20 antibody and an alkylating agent.

Findings from the study showed that treatment with mosunetuzumab led to 80% of pretreated patients to have durable response rates. Additionally, the complete remission rate in the single-arm, multicenter, phase 2 study was 60%.


0:08 | For follicular lymphoma, we have important updates on the activity and durability of responses with the treatment with mosunetuzumab. Mosunetuzumab is a novel bispecific antibody targeting CD20 and CD3, creating an immune synapse with healthy T cells. This has been described in prior [meetings] and publications and clearly is an active medicine in patients with multimodal follicular lymphoma, with overall response rates of 80% and complete response [CR] rates of 60%.

0:47 | The important question, however, is how durable are these responses? We now have maturing data, with a median follow-up now of 27 months. We see that the median duration of response, CR, and even median progression-free survival have not yet been reached, which for me, emphasizes the point that not only is this agent highly active in relapsed [follicular lymphoma], but the responses are quite durable.

Related Videos
Related Content